Wolfgang Stremmel was born 22 April 1952 in Cologne (Germany).

EDUCATION AND TRAINING
1976 – Federal Examination in Medicine, University of Cologne
1977 – Dr. med.  – Doctorate Degree in Medicine at the Dept. of Biochemistry, University of Cologne
1984 – Boards in Internal Medicine, University of Düsseldorf
1985 – Habilitation in Internal Medicine, University of Düsseldorf
1987 – Boards in Gastroenterology, University of Düsseldorf

FELLOWSHIPS AND EMPLOYMENTS
1976-1977 Doctoral Fellowship, Dept. of Biochemistry, University of Cologne
1977-1978 Research Fellow, Dept. of Biochemistry, University of Cologne
1978-1980 Fellow in Internal Medicine, University of Düsseldorf
1980-1982 Research Fellow, Mt. Sinai School of Medicine, New York,N.Y.
1982-1987 Fellow in Internal Medicine, University of Düsseldorf
1987-1988 Senior Fellow (C2) in Internal Medicine, University of Düsseldorf
1989 Appointment as extraordinary Professor of Medicine
University of Düsseldorf
1991-1994 Professor of Internal Medicine (C3), Senior Fellow
Dept. of Internal Medicine, University of Düsseldorf
1994- today Chief, Dept. of Gastroenterology and Infectious Diseases
Professor of Internal Medicine (C4), University Hospital of Heidelberg

AWARDS
1985 Thannhauser Award, German Gastroenterological Association
1988 European Award of Gastroenterology
1989 Gottfried Wilhelm Leibniz Award of the German Research Council
(DFG)
2002 Teaching Award of the Faculty of Medicine, University of Heidelberg
2006 Honorary doctoral degree of the University of Medicine, Tbilisi, Georgia

FUNDINGS
1998-2000 Deutsche Forschungsgemeinschaft, project coordinator of SFB 601
„Molecular Pathogenesis of Hepatogastroenterological Diseases“
1980-2013 Deutsche Forschungsgemeinschaft, continuous project funding
2009-2013 Deutsche Forschungsgemeinschaft, current funding:
Wirkungsmechanismus des Gallensäure-Phospholipid Konjugates
Ursodeoxycholat-Lysophosphatidylethanolamid (UDCA-LPE) auf die
Fettsäureaufnahme in Hepatozyten: Bedeutung für seinen
therapeutischen Einsatz bei nicht-alkoholischer Fettleberhepatitis (NASH)
2011-2014 Phospholipid Research Center, Heidelberg:
Mechanistic action and adverse events of therapy with delayed release
phosphatidylcholine in a genetic mouse model of ulcerative colitis

SCIENTIFIC FIELDS OF INTEREST
Clinical
– fat absorption, -malabsorption
– lipid based therapy
– metabolic liver disease
– ulcerative colitis
Basic
– phosphatidylcholine secretion in intestine
– cellular uptake and metabolism of fatty acids
– cellular uptake of iron
– intracellular transport of copper
– treatment of ulcerative colitis with delayed released phosphatidylcholine
– treatment of non-alcoholic steatohepatitis (NASH) with the bile acid phospholipid
conjugate UDCA-LPE

TEN REPRESENTATIVE REFERENCES OF THE MAIN TOPICS OF RESEARCH
Stremmel, W., Staffer, S., Wannhoff, A., Pathil, A., and Chamulitrat, W. Plasma membrane phosphoplipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis. The FASEB J. 2014, 28 (7): p. 3159-3170, IF 5.4

Pathil, A., Müller, J., Warth, A., Chamulitrat, W., Stremmel, W. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology 2012, 55: 1369-78, IF 11.4

Weiss, K.H., Gotthardt, D.N., Klemm, D., Merle, U., Ferenci-Foerster, D., Schaefer, M., Ferenci, P., Stremmel, W. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson’s disease. Gastroenterology. 2011. 140(4): p.1189-1198 e1, IF 11.7

Merle, U., Eisenbach, C., Weiss, K.H., Tuma, S., and Stremmel, W. Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson’s disease. J. Hepatol. 2009. 51(5): p. 925-30, IF 9.3

Chamulitrat, W., Burhenne, J., Rehlen, T., Pathil, A,, Stremmel, W. Bile salt-phosholipid conjugate ursodeoxychol lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology 2009; 50: 143-154, IF 11.4

Stremmel, W., Ehehalt, R., Autschbach, F., Karner, M. Phosphatidylcholine for steroidrefractory hronic ulcerative colitis: a randomized trial. Ann Intern Med 2007; 147: 603-610, IF 16.7

Ferenci, P., Czlonkowska, A., Merle, U., Ferenc, S., Gromadzka, G., Yurdaydin, C., Vogel, W., Bruha, R., Schmidt, H.T., and Stremmel, W., Late-onset Wilson’s disease. Gastroenterology, 2007. 132(4): p. 1294-8, IF 11.7

Merle, U., Schaefer, M., Ferenci, P., and Stremmel, W., Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut, 2006. 56(1): p. 115-20, IF 10.1

Stremmel, W., Merle, U., Zahn, A., Autschbach, F., Hinz, U., and Ehehalt, R., Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut, 2005. 54(7): p. 966-71, IF 10.1

Herrmann .T., van der Hoeven, F., Grone, H.J., Stewart, A.F., Langbein, L., Kaiser, I., Liebisch, G., Gosch, I., Buchkremer, F., Drobnik, W., Schmitz, G., Stremmel, W. Mice with targeted disruption of the fatty acid transport protein 4 (Fatp 4, Slc27a4) gene show features of lethal restrictive dermopathy. J Cell Biol 2003; 161(6) 1105-15; IF 10.3